# The Synergy of ChemMatrix Resin® and Pseudoproline Building Blocks Renders RANTES, A Complex Aggregated Chemokine*

Fayna García-Martín[1]
Peter White[2]
René Steinauer[3]
Simon Côté[4]
Judit Tulla-Puche[1]
Fernando Albericio[1,5]

[1] Institute for Research in Biomedicine, Barcelona Science Park, University of Barcelona, Josep Samitier 1, 08028—Barcelona, Spain

[2] Novabiochem Merck Biosciences Ltd., NG9 2JR Beeston, Nottingham, United Kingdom

[3] Merck Biosciences AG, Weidenmattweg 4, 4448 Läufelfingen, Switzerland

[4] Matrix Innovation, Inc., 1450 City Councillors, Suite 230, Montreal, Québec, Canada

[5] Department of Organic Chemistry, University Barcelona, Martí i Franqués 1, 08028—Barcelona, Spain

*Received 10 May 2006;*
*revised 21 June 2006;*
*accepted 24 June 2006*
*Published online 29 June 2006 in Wiley InterScience (www.interscience.wiley.com).*
*DOI 10.1002/bip.20564*

**Abstract:** *Traditionally, solid-phase synthesis has relied on polystyrene-based resins for the synthesis of all kinds of peptides. However, due to their high hydrophobicity, these resins have certain limitations, particularly in the synthesis of complex peptides, and in such cases, poly(ethylene glycol) (PEG)-based resins are often found to give superior results. Another powerful strategy for expediting the assembly of complex peptides is to employ pseudoproline dipeptides. These derivatives disrupt the interactions among chains that are usually the cause of poor coupling yields in aggregated sequences. Here we report on an efficient stepwise solid-phase synthesis of RANTES (1–68) by combining the advantages of the totally PEG-based ChemMatrix® resin and pseudoproline dipeptides.* © 2006 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 84: 566–575, 2006

*This article was originally published online as an accepted preprint. The "Published Online" date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at biopolymers@wiley.com*

**Keywords:** *RANTES; chemokines; poly(ethylene glycol)-based resins; pseudoproline dipeptides; aggregating peptides*

*Correspondence to:* Judit Tulla-Puche; e-mail: jtulla@pcb.ub.es or Fernando Albericio; e-mail: albericio@pcb.ub.es

Contract grant sponsor: CICYT, Generalitat de Catalunya, Institute for Research in Biomedicine, and Barcelona Science Park
Contract grant number: BQU 2003-00089 (CICYT)

*Abbreviations used for amino acids and the designations of peptides follow the IUPAC-IUB Commission of Biochemical Nomenclature in *Journal of Biological Chemisty,* 1982, Vol. 247, pp. 977–983. Amino acid symbols denote L-configuration.

Biopolymers (Peptide Science), Vol. 84, 566–575 (2006)
© 2006 Wiley Periodicals, Inc.

## INTRODUCTION

In recent years, several peptides, such as T-20, Eptifibatide, Ziconotide, Pramlintide, Exenatide, and Bivalirudin, have been approved by the U.S. Food and Drug Administration and are on the market for use in the treatment of various diseases. More importantly, at the end of 2004, more than 600 peptides were either in development or advanced preclinical phases.[1] This explosion of peptides onto the pharmaceutical market has been possible, in part, because chemical synthetic methods, mainly solid-phase approaches, have reached a high level of efficacy. A large arsenal of chemical tools is now available for the synthesis of almost all peptides up to ca. 40 residues. However, several small–medium size peptides and many large peptides and/or proteins are still unavailable by classical methods. One example is RANTES, a 68 amino acid chemokine (Figure 1) that has a high propensity to aggregate.[2,3]

This protein has been obtained mainly by intracellular expression in *Escherichia Coli* or secretion from insect cells.[4] An analogue, the aminooxypentane oxime of [glyoxylyl[1]]RANTES (2–68) (AOP-RANTES), has been synthesized by native chemical ligation.[5,6] Here the full peptide was divided in two fragments, AOP-RANTES (2–33)-$\alpha$-thioester and RANTES (34–68), which were assembled separately by *tert*-butyloxycarbonyl (Boc) chemistry and then coupled. The stepwise synthesis of the full peptide has been previously described by one of us.[7] That study showed that, at an elevated temperature, a polyethylene glycol (PEG)–polystyrene solid support (PS) resin in combination with 1-[bis(dimethylamino)-methylene]-1*H*-1,2,3-triazolo-[4,5-*b*]pyridinium hexafluorophosphate 3-oxide (HATU) as coupling reagent and "magic mixture" as a solvent allowed an effective synthesis of 40–60 residues. Unfortunately, high performance liquid chromatography (HPLC) analysis of RANTES (1–68) indicated that the coupling and deprotection procedures employed did not provide a definitive optimal method.[7] Here we report that the combined application of the ChemMatrix® resin,[8] a totally PEG-based solid support, and pseudoproline dipeptides allows the stepwise solid-phase synthesis of RANTES (1–68).

## EXPERIMENTAL

### General

Aminomethyl-ChemMatrix® resin was provided by Matrix Innovation, Canada. Pseudoproline dipeptides and other protected amino acids, Fmoc–Ser(*t*Bu)–PS–Wang resin (Fmoc: 9-fluorenylmethoxycarbonyl; *t*Bu, *tert*-butyl) (100–200 mesh) and coupling reagents were obtained from Novabiochem (Laüfelfingen, Switzerland). HPLC was performed on a reversed-phase $C_{18}$ (4.6 × 150 mm, 5 $\mu$m) or $C_8$ column (2.1 × 50 mm, 3.5 $\mu$m), as indicated in each case. Linear gradients of 0.045% trifluoroacetic acid (TFA) and 0.036% in acetonitrile ($CH_3CN$) were run at flow rates of 1.0 and 0.5 mL/min for the $C_{18}$ and the $C_8$ column, respectively. HPLC-MS was performed on a reversed-phase $C_{18}$ column (3.9 × 150 mm, 5 $\mu$m). Aqueous (0.1%) formic acid and formic acid (0.07%) in $CH_3CN$ were used as eluents. For both HPLC and HPLC-MS, linear gradients from 10 to 60% were run over 15 min, unless otherwise indicated. MALDI-TOF MS (matrix assisted laser desorption–time of flight mass spectroscopy)was performed on a MALDI Voyager DE RP time-of-flight (TOF) spectrometer (PE Biosystems, Foster City, CA).

### Cleavage

The peptides were cleaved from the resins with simultaneous removal of side-chain protective groups by treatment with reagent K (TFA–phenol–$H_2O$–thioanisole–1,2-ethanedithiol, 82.5:5:5:5:2.5) for 2 and 3 h at room temperature. A ratio of 100 $\mu$L of cleavage cocktail per mg of resin was used. Following the cleavage reaction, peptides were precipitated by adding cold *tert*-butylmethyl ether. The solution was then decanted, and the solid was triturated with cold *tert*-butylmethyl ether, which was decanted again. This process was repeated twice, and peptides were finally dissolved in 10% acetic acid and lyophilized.

### Attempts to Synthesize RANTES

***Manual Synthesis: Polystyrene Resin Without Pseudoproline ($\psi$Pro) (Table I, No. 1).*** Solid-phase peptide elongation was performed in polypropylene syringes, each fitted with a polyethylene porous disk. Solvents and soluble reagents were removed by suction.

The peptide was manually synthesized on Fmoc–Ser(*t*Bu)–PS–Wang resin (0.036 mmol, 0.24 mmol/g). Coupling reactions were carried out with Fmoc-amino acids (3 eq.), HATU (3 eq.), 1-hydroxy-7-azabenzotriazole

H-Ser-Pro-Tyr-Ser-Ser-Asp-Thr-Thr-Pro$^{9}$-Cys-Cys-Phe-Ala-Tyr-Ile-Ala-Arg-Pro-Leu$^{19}$-Pro-Arg-Ala-His-Ile-Lys-Glu-Tyr-Phe-Tyr$^{29}$-Thr-Ser-Gly-Lys-Cys-Ser-Asn-Pro-Ala-Val$^{39}$-Val-Phe-Val-Thr-Arg-Lys-Asn-Arg-Gln-Val$^{49}$-Cys-Ala-Asn-Pro-Glu-Lys-Lys-Trp-Val-Arg$^{59}$-Glu-Tyr-Ile-Asn-Ser-Leu-Glu-Met-Ser$^{68}$-OH

**FIGURE 1** Amino acid sequence of RANTES (1–68).



10970282a, 2006, 6, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/bip.20564 by Universidad de la Rioja, Wiley Online Library on [08/02/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

**Table I Strategies to Synthesize RANTES (1–68) Peptide**

| No. | Resin | ΨPro | Fragment Obtained |
|---|---|---|---|
| 1 | PS (manual) | No | 44–68 |
| 2 | PS | No | 43–68 |
| 3 | PS | $D^6T^7$, $Y^{29}T^{30}$, $V^{42}T^{43}$, $N^{63}S^{64}$ | 24–68 |
| 4 | PEG | $D^6T^7$, $V^{42}T^{43}$, $N^{63}S^{64}$ | 1–68 (21%) |
| 5 | PEG | $D^6T^7$, $Y^{29}T^{30}$, $V^{42}T^{43}$, $N^{63}S^{64}$ | 1–68 (31%) |

(3-hydroxy-3*H*-1,2,3-triazolo-[4,5-*b*]pyridine (HOAt) (3 eq.), and *N*,*N*-diisopropylethylamine (DIEA) (6 eq.). Fmoc was removed with piperidine–*N*,*N*-dimethylformamide (DMF) (1:4) (2 × 5 min, 2 × 10 min). Double couplings were performed at $Tyr^{61}$, $Ala^{51}$, $Arg^{47}$, $Asn^{46}$, $Lys^{45}$, and $Arg^{44}$. Washings between deprotection, coupling, and subsequent deprotection steps were performed with DMF (5 × 0.5 min) and $CH_2Cl_2$ (5 × 0.5min) using 10 mL of solvent/g of resin each time. The coupling and deprotection steps were monitored by Kaiser and De Clercq tests and Fmoc was measured by ultraviolet (UV) every two or three amino acids. To verify the course of the synthesis, four samples were taken and characterized by HPLC and MALDI-TOF MS. An acceptable HPLC profile was obtained only until $Arg^{59}$. The sample at $Arg^{44}$ was analyzed by HPLC and a complex chromatogram was obtained. HPLC-MS showed a minor peak corresponding to the expected mass ($t_R$ 7.14; *m*/*z* calcd. for $C_{132}H_{217}N_{42}O_{39}S_2$, 3077.6; found, 3079.0 $[M + H]^+$), and MALDI-TOF MS (*m*/*z* calcd. for $C_{132}H_{217}N_{42}O_{39}S_2$, 3077.6; found, 3078.2 $[M + H]^+$) (see Figure 4).

***General Method for Automatic Synthesis.*** Peptide chains were elongated by means of an ABI 433A peptide synthesizer (Applied Biosystems, Foster City, CA) using standard Fmoc chemistry and FastMoc MonPrevPk′. Syntheses were conducted on a 0.1- or 0.04-mmol scale, indicated in each case, with a ten-fold excess of Fmoc-protected L-amino acids and pseudoproline dipeptides Fmoc–Asn(Trt)$^{63}$–Ser($\psi^{Me,Me}$Pro)$^{64}$–OH (Trt: trityl), Fmoc–Val$^{42}$–Thr-($\psi^{Me,Me}$Pro)$^{43}$–OH, Fmoc–Tyr(*t*Bu)$^{29}$–Thr($\psi^{Me,Me}$Pro)$^{30}$–OH, and Fmoc–Asp(O*t*Bu)$^{6}$–Thr($\psi^{Me,Me}$Pro)$^{7}$–OH, as indicated in each attempt. HATU 0.28 or 0.16*M* (depending on the scale) in DMF was used as coupling reagent. A 35-min coupling was performed on all amino acids except for $Val^{38}$, for which a double coupling was required. Fmoc was removed by a 15-min treatment with piperidine–DMF (1:4). In syntheses 2 and 3, half the resin was removed after residue $Arg^{44}$ to reduce the volume of the resin bed. From this residue onwards, the concentration of coupling reagent was reduced by half. After the assembly was completed, the peptide–resin was washed with $CH_2Cl_2$.

**Polystyrene Resin Without $\psi$Pro (Table I, No. 2).** Synthesis was performed on Fmoc–Ser(*t*Bu)–PS–Wang resin (0.036 mmol, 0.24 mmol/g) and using HATU (0.16*M* in DMF) as coupling reagent. After $Arg^{44}$, half of the resin was separated. From this step on, the concentration of coupling reagent was decreased to 0.081*M*. To verify the course of the synthesis, nine resin samples were taken at various points during the assembly and the peptides cleaved from them as previously described. The products obtained from these samples, together with the final one, were characterized by HPLC and MALDI-TOF MS. The product sampled at $Arg^{44}$ gave a peak ($t_R$ 6.62) that corresponded to the peptide of interest: HPLC-MS (*m*/*z* calcd. for $C_{132}H_{217}N_{42}O_{39}S_2$, 3077.6; found, 1539.0 $[M + H]^+/2$, 1026.6 $[M + H]^+/3$; 769.7 $[M + H]^+/4$, 615.4 $[M + H]^+/5$) (see Figure 6a). However, characterization of the product obtained from the resin taken at $Ser^{31}$ by HPLC-MS indicated that the peptide of interest (*m*/*z* calcd. for $C_{189}H_{308}N_{57}O_{56}S_3$, 4368.2) was not present in the sample. The major peak ($t_R$ 7.18 min) corresponded to the peptide terminating at $Thr^{43}$ (*m*/*z* calcd. for $C_{136}H_{224}N_{43}O_{41}S_2$, 3178.6; found, 1060.5 $[M + H]^+/3$, 635.9 $[M + H]^+/5$).

**Polystyrene Resin With $\psi$Pro (Table I, No. 3).** This synthesis was carried out as described above, except that $\psi$Pro dipeptides Fmoc–Asn(Trt)–Ser($\psi^{Me,Me}$Pro)–OH, Fmoc–Val–Thr($\psi^{Me,Me}$Pro)–OH,Fmoc–Tyr(*t*Bu)–Thr($\psi^{Me,Me}$Pro)–OH, and Fmoc–Asp(O*t*Bu)–Thr($\psi^{Me,Me}$Pro)–OH were used to introduce residues $N^{63}S^{64}$, $V^{42}T^{43}$, $Y^{29}T^{30}$, and $D^6T^7$, respectively. After coupling of $Arg^{44}$, half of the resin was removed. From this step on, the concentration of coupling reagent was decreased to 0.081*M*. As in synthesis 2, nine resin samples were taken and the peptides cleaved as previously described. These products, together with the final one, were characterized by HPLC and MALDI-TOF MS. The product sampled at $Arg^{44}$ gave a major peak ($t_R$ 6.13 min, 63%) by HPLC, which was verified by HPLC-MS as the target peptide (*m*/*z* calcd. for $C_{132}H_{217}N_{42}O_{39}S_2$, 3077.6; found, 1540.0 $[M + H]^+/2$, 1026.6 $[M + H]^+/3$; 769.9 $[M + H]^+/4$, 616.7 $[M + H]^+/5$, 513.6 $[M + H]^+/6$) (see Figure 6b). For the sample taken at $Ile^{24}$, analytical HPLC gave a major peak ($t_R$ 7.43 min, 44%), which was characterized by HPLC-MS (*m*/*z* calcd. for $C_{237}H_{372}N_{65}O_{68}S_3$, 5311.7; found, 886.3 $[M + H]^+/6$, 759.6 $[M + H]^+/7$, 664.6 $[M + H]^+/8$, 591.1 $[M + H]^+/9$) and MALDI-TOF MS (*m*/*z* calcd. for $C_{237}H_{372}N_{65}O_{68}S_3$, 5311.7; found, 5312.7 $[M + H]^+$) as the peptide of interest (see Figure 7).

**ChemMatrix® Resin With $\psi$Pro.** This synthesis was performed on the Wang–ChemMatrix® PEG–resin (0.09 mmol, 0.60 mmol/g). The first amino acid was coupled manually as follows: Fmoc–Ser(*t*Bu)–OH (4 eq.), 1-(2-mesitylenesulfonyl)-3-nitro-1H-1,2,4-triazole (MSNT) (4 eq.), *N*-methylimidazole (NMI) (8 eq.), and DIEA (12 eq.) in $CH_2Cl_2$ at room temperature for 5 h.[9] Next, an acetylation step was carried out using $Ac_2O$–DIEA ($Ac_2O$: acetic anhydride) (50 eq. each) in DMF for 15 min. On the basis of Fmoc quantification, a loading of 0.42 mmol/g was determined. The remaining peptide chain elongation was done on an automatic synthesizer using HATU (0.28*M*) as coupling



10970282a, 2006, 6, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/bip.20564 by Universidad de la Rioja, Wiley Online Library on [08/02/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




**FIGURE 2** $Val^{42}$–Thr($\psi^{Me,Me}$Pro)$^{43}$ on RANTES synthesis. Upon cleavage, the pseudoproline renders $Val^{42}$–$Thr^{43}$.

reagent. Four samples were taken and analyzed. $\psi$Pro dipeptides [Fmoc–Asn(Trt)–Ser($\psi^{Me,Me}$Pro)–OH and Fmoc–Val–Thr($\psi^{Me,Me}$Pro)–OH] were used to introduce residues $N^{63}S^{64}$ and $Val^{42}T^{43}$, respectively. After introduction of $Ser^{31}$, the resin was divided into two equal portions and assembly was continued separately on each as described below.

*Using Three $\psi$Pro Dipeptides. (Table I, No. 4).* The synthesis was continued as described above. Residues $D^6T^7$ were introduced using Fmoc–Asp(O*t*Bu)–Thr($\psi^{Me,Me}$Pro)–OH. Another sample was taken to verify the course of the synthesis. The final peptide was characterized by HPLC ($t_R$ 7.97, 21%) and MALDI-TOF MS (*m*/*z* calcd. for $C_{350}H_{539}N_{96}O_{100}S_5$, 7846.8; found, 7847.3 $[M + H]^+$) (see Figure 8).

*Using Four $\psi$Pro Dipeptides (Table I, No. 5).* The synthesis continued with the remaining half of the resin separated at $Ser^{31}$, using Fmoc–Tyr(*t*Bu)$^{29}$–Thr($\psi^{Me,Me}$Pro)$^{30}$–OH and Fmoc–Asp(O*t*Bu)–Thr($\psi^{Me,Me}$Pro)–OH for the incorporation of residues $Y^{29}T^{30}$ and $D^6T^7$, respectively. A final sample was taken and checked. The final peptide was characterized by HPLC ($t_R$ 7.99, 31%) and MALDI-TOF MS (*m*/*z* calcd. for $C_{350}H_{539}N_{96}O_{100}S_5$, 7846.8; found, 7851.0 $[M + H]^+$) (see Figure 9).

***Purification.*** An aliquot of the crude RANTES, obtained as described above, was solved in 7.3*M* guanidinium HCl, 0.5% EDTA, 0.1*M* Tris · HCl, pH 8.2 and purified on an analytical reverse-phase $C_8$ column, using a linear gradient of 0.045% aqueous TFA–0.036% TFA in $CH_3CN$, from 10 to 60% over 15 min, with a flow rate of 0.5 mL/min. The purified peptide was characterized under reducing conditions by HPLC ($t_R$ 7.14, 90%) and MALDI-TOF MS (*m*/*z* calcd. for $C_{350}H_{539}N_{96}O_{100}S_5$, 7846.8; found, 7848.5 $[M + H]^+$) (see Figure 10).

## RESULTS AND DISCUSSION

Although the synthesis of peptides containing hindered amino acids can be accomplished by the concourse of highly reactive coupling methods[10,11] such as HATU[12] or *N*,*N*,*N*′,*N*′-tetramethylformamidinium hexafluorophosphate (TFFH),[13] that of large and well-structured peptides requires additional synthetic tools. In such cases, intra- and interchain interactions can be minimized by special solvents, such as the so-called magic mixtures[14] or those containing chaotropic salts,[15] by structure disrupters such as Pro residues[16] or protected amide bonds,[17] and by resins that facilitate the solvation of peptide chains.[18,19]

The present work explores the application of pseudoproline ($\psi$Pro) dipeptides in combination with a total PEG–resin to overcome aggregation and thus achieve the desired peptide.

$\psi$Pro dipeptides consist of a dipeptide in which the Ser, Thr, or Cys residue has been reversibly protected as proline-like TFA-labile oxazolidine (Figure 2).[20,21] Just like Pro, the insertion of a pseudoproline residue into a sequence disrupts the aggregation thought responsible for the problems encountered during peptide assembly.[22] Once peptide chain elongation has been accomplished, the final acidic treatment that detaches the peptide from the resin and removes the side-chain protecting groups of the amino acids also opens the oxazolidine ring, thereby releasing the natural amino acids. $\psi$Pro residues are incorporated using pre-formed dipeptides because the poor nucleophilicity of the secondary oxazolidine amino function would prevent the solid-phase incorporation of the next amino acid.

Furthermore, our groups have recently succeeded in obtaining difficult short- and medium-sized peptides using ChemMatrix® resin (Figure 3), a total PEG resin.[8] PEG-based resins were independently developed by Meldal and coworkers[23,24] and Côté.[25] The optimal properties of the PEG are due to the vicinal arrangements of carbon–oxygen bonds throughout the chain, which make the PEG assume helical struc-



**FIGURE 3** ChemMatrix® bead resins by Electronic Microscopy.



10970282a, 2006, 6, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/bip.20564 by Universidad de la Rioja, Wiley Online Library on [08/02/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




**FIGURE 4** *Table I, No. 1.* HPLC chromatogram of RANTES ($Arg^{44}$–$Ser^{68}$) manually synthesized on PS resin and using HATU/HOAt as coupling reagent. HPLC conditions: $C_{18}$ column, linear gradient 0.1% aqueous TFA–0.1% TFA in $CH_3CN$, from 10 to 60% over 15 min, flow rate of 1.0 mL/min.

tures with *gauche* interactions between polarized bonds.[26] PEG can exhibit three helical arrangements: the first, largely hydrophobic; the second, of intermediate hydrophobicity; and the third, hydrophilic. The amphiphilic nature of PEG makes the resin well solvated in both polar and nonpolar solvents and disrupts backbone interactions,[26] and gives usually superior results when compared with PS resins.[8,23,24,27]

Our initial attempts to prepare RANTES by a classical stepwise Fmoc solid-phase strategy on polystyrene resin failed to deliver the expected peptide, despite trying a range of coupling reagents and manual and automatic synthesis conditions. For instance, a manual synthesis starting with low-loading Wang–PS–resin [Fmoc–Ser(*t*Bu)–O–Wang–PS–resin, 0.24 mmol/g] and HATU/HOAt, considered one of the most efficient coupling methods,[12] gave an extremely poor yield of RANTES $Arg^{44}$–$Ser^{68}$ (25 amino acids) (Figure 4).

To overcome these difficulties, the use of $\psi$Pro dipeptides was then evaluated. When using this strategy, the choice of the key residues Thr or Ser to be replaced by $\psi$Pro residues is crucial because the proline motif provides a deliberate change of native structure, usually in the region of 6–10 residues after its incorporation, thereby improving the efficacy of synthesis. The RANTES sequence contains the following replaceable residues: $Ser^{68}$, $Ser^{64}$, $Thr^{43}$, $Ser^{35}$, $Thr^{30}$, $Thr^{8}$, $Thr^{7}$, $Ser^{5}$, and $Ser^{4}$. $Ser^{64}$ is located close to the




**FIGURE 5** Scheme of part of the $\beta$-sheet of the RANTES structure. Circled amino acids were incorporated as $\psi$Pro dipeptides.



10970282a, 2006, 6, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/bip.20564 by Universidad de la Rioja, Wiley Online Library on [08/02/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




**FIGURE 6** Synthesis of RANTES, Sample Arg[44]. (a) *Table 1, No. 2*, PS resin, without using $\psi$Pro dipeptides. (b) *Table I, No. 3*. PS resin, using $\psi$Pro dipeptides. HPLC conditions: $C_{18}$ column, linear gradient 0.1% aqueous TFA–0.1% TFA in $CH_3CN$, from 10 to 60% over 15 min, flow rate of 1.0 mL/min.

*C*-terminal, and therefore the $\psi$Pro [Fmoc–Asn (Trt)[63]–Ser($\psi^{Me,Me}$Pro)[64]–OH] was introduced into this *C*-terminal part to initially alter chain conformation. According to the structural analysis by Chung et al.,[28] and corroborated by our own preliminary synthesis, the critical part of the sequence falls between residues 53 and 22. In particular, hydrogen bonds formed by Thr[30] and Thr[43] are energetically important and crucial during folding, as they are the first to be formed. Incorporation of $\psi$Pro at the turn positions destabilizes these hydrogen bonds, thereby preventing $\beta$-sheet formation. By taking advantage of these Thr's, two $\psi$Pro dipeptides were chosen in this region, Val[42]–Thr($\psi^{Me,Me}$Pro)[43] and Tyr(*t*Bu)[29]–Thr($\psi^{Me,Me}$Pro)[30], which are located on distinct sheets in the backbone of the native peptide (Figure 5).

Previous studies on the synthesis of this large and complex peptide concluded that the *N*-terminal region is also a difficult part.[7] Thus the $\psi$Pro dipeptide Asp(O*t*Bu)[6]–Thr($\psi^{Me,Me}$Pro)[7] was selected in this region.[†]

[†]Alternatively, the Fmoc–Thr(*t*Bu)[7]–Thr($\psi$Me,MePro)[8]–OH could have been inserted, but both these $\beta$-branched building blocks are of more difficult preparation and its incorporation as dipeptide on Pro[9] would also be more difficult.



10970282a, 2006, 6, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/bip.20564 by Universidad de la Rioja, Wiley Online Library on [08/02/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




**FIGURE 7** *Table I, No. 3*. Synthesis of RANTES using four ψPro dipeptides on PS resin, Sample Ile[23]. HPLC conditions: $C_{18}$ column, linear gradient 0.1% aqueous TFA–0.1% TFA in $CH_3CN$, from 10 to 60% over 15 min, flow rate of 1.0 mL/min.

Two automatic syntheses with and without ψPro dipeptides of the RANTES sequence were performed on PS using HATU as coupling reagent. Syntheses were analyzed at several points during the process. Thus, in the synthesis carried out with regular amino acids only, the peptide obtained from the sample taken at Arg[44] (25 amino acids) showed a peak ($t_R$ 6.36 min) corresponding to the peptide of interest, and should hypothetically allow the isolation of this fragment (Figure 6a).[‡] The peptide from the next sample taken at Ser[31] (38 amino acids), however, did not show a mass that could be identified by HPLC-MS with the target peptide.

In contrast, the synthesis performed using similar experimental conditions but with the use of ψPro dipeptides progressed more smoothly. Thus, the peptide obtained from the sample taken at Arg[44] (26 amino acids), where the ψPro dipeptide Asn(Trt)[63]–Ser($\psi^{Me,Me}$Pro)[64] was incorporated, showed a major peak ($t_R$ 6.31 min), corresponding to the peptide of interest, which should be easily isolated (Figure 6b). Furthermore, the product from the sample at Ser[31] (38 amino acids), where the second ψPro,Val[42]–Thr($\psi^{Me,Me}$Pro)[43] was also incorporated, showed a large peak by HPLC-MS, which corresponded to the target peptide (data not shown). Unfortunately, the product from the sample at Ile[24] (45 amino acids) was the last one in which a peak corresponding to the target peptide could be identified (Figure 7).[§]

These results indicate that although the use of ψPro dipeptides clearly benefits the synthesis of RANTES, the effects of their incorporation are insufficient to allow the assembly of the full-length peptide in good yield. Consequently, the synthesis of RANTES was then repeated using ψPro dipeptides in combination with the ChemMatrix® resin; as in our previous experiences, the use of this amphiphilic resin could be anticipated to significantly improve the synthetic efficiency of this hydrophobic peptide.[23] A new synthesis was therefore undertaken using Fmoc–Ser(*t*Bu)–O–Wang–ChemMatrix® resin. The higher substitution of this resin (0.41 mmol/g) when compared with the PS resin (0.24 mmol/g) was not anticipated to negatively effect the synthesis, owing to the unique architecture of this polymer. Residues 63 and 64 and 42 and 43 were incorporated using ψPro dipeptides Asn(Trt)[63]–Ser($\psi^{Me,Me}$Pro)[64] and Val[42]–Thr($\psi^{Me,Me}$Pro)[43]. The resin was divided in two portions at residue 31 to evaluate the beneficial effect of introducing a ψPro residue at Thr[30]. With one portion of the resin, the "classical" amino acid Fmoc–Thr(*t*Bu)–OH was introduced at residue 30, whereas in the second, Tyr(*t*Bu)[29]–Thr($\psi^{Me,Me}$Pro)[30] was used to introduce Tyr[29]–Thr[30]. In both syntheses, the ψPro

[‡]An additional conclusion of the two syntheses discussed is that automatic synthesis very often performed better than the manual ones.

[§]At this stage, a short study of several cleavage methods was performed. Reagent K gave clearly better results than the other methods tested.



10970282a, 2006, 6, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/bip.20564 by Universidad de la Rioja, Wiley Online Library on [08/02/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




**FIGURE 8** *Table I, No. 4*. Synthesis of RANTES using 3 $\psi$Pro dipeptides, on ChemMatrix® resin. HPLC conditions: $C_8$ column, linear gradient 0.1% aqueous TFA–0.1% TFA in $CH_3CN$, from 10 to 60% over 10 min, flow rate of 0.5 mL/min.

dipeptide Asp(O*t*Bu)$^6$–Thr($\psi^{Me,Me}$Pro)$^7$ was introduced in place of Asp$^6$–Thr$^7$. In both cases, a major peak corresponding to the desired final RANTES peptide was obtained (Figure 8 and 9). Moreover, the HPLC profile was notably improved when all four $\psi$Pro dipeptides were used (Figure 9). In this case, the MALDI-TOF MS confirmed the success of the approach that combines the full PEG resin, ChemMatrix®, and $\psi$Pro dipeptides to disrupt backbone interactions.

Finally, the peptide was purified under reducing conditions and the desired sequence was obtained




**FIGURE 9** *Table I, No. 5*. Synthesis of RANTES using 4 $\psi$Pro dipeptides, on ChemMatrix® resin. HPLC conditions: $C_8$ column, linear gradient 0.1% aqueous TFA–0.1% TFA in $CH_3CN$, from 10 to 60% over 10 min, flow rate of 0.5 mL/min.



10970282a, 2006, 6, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/bip.20564 by Universidad de la Rioja, Wiley Online Library on [08/02/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License




**FIGURE 10** Purified RANTES. a) HPLC ($t_R$ 7.14, 90%). HPLC conditions: peptide dissolved in 6*M* guanidine, using a $C_8$ column, linear gradient 0.1% aqueous TFA–0.1% TFA in $CH_3CN$, from 10 to 60% over 15 min, flow rate of 0.5 mL/min. b) MALDI-TOF MS (7848.5, $[M + H^+]$).

with a 90% purity and was then verified by MALDI-TOF MS using the linear mode (Figure 10).

## CONCLUSIONS

Although ChemMatrix® resin and $\psi$Pro dipeptides have been separately demonstrated to be excellent strategies for the synthesis of complex and/or large peptides, here we show that the concomitant use of both allows the stepwise synthesis of an even greater range of large peptides and proteins. The synergy between the two methods should boost research in several therapeutic areas.

This work was partially supported by CICYT (BQU 2003-00089), Generalitat de Catalunya, the Institute for Research in Biomedicine, and the Barcelona Science Park. We thank Saint-Jean Photochimie, St-Jean-sur-le-Richelieu, Québec, Canada, for the electronic microscopy images.

## REFERENCES

1. Marx, V. Chem Eng News 2005, 83, 17–24.
2. Cocchi, F.; DeVico, A. L.; Garzino-Demo, A.; Arya, S. K.; Gallo, R. C.; Lusso, P. Science 1995, 270, 1811–1815.
3. Nardesse, V.; Longhi, R. Nat Struct Biol 2001, 8, 611–615.



10970282a, 2006, 6, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/bip.20564 by Universidad de la Rioja, Wiley Online Library on [08/02/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

4. Proudfoot, A. E. I.; Wells, N. C.; Power, C. A. Chemokine Protocols. Methods in Molecular Biology; Humana Press: Totowa, NJ; 2000; Vol 138.
5. Wilken, J.; Hoover, D.; Thompson, D. A.; Barlow, P. N.; McSparron, H.; Picard, L.; Wlodawer, A.; Lubkowski, J.; Kent, S. B. H. Chem Biol 1999, 6, 43–51.
6. Hartley, O.; Gaertner, H.; Wilken, J.; Thompson, D.; Fish, R.; Ramos, A.; Pastore, C.; Dufour, B.; Cerini F.; Melotti, A.; Heveker N.; Picard, L.; Alizon, M.; Mosier, D.; Kent, S.; Offord, R. Proc Natl Acad Sci 2004, 101, 16460–16465.
7. McNamara, J. F.; Lombardo, H.; Pillai, S. K.; Jensen, I.; Albericio, F.; Kates, S. A. J Pept Sci 2000, 6, 512–518.
8. García-Martin, F.; Quintanar-Audelo, M.; García-Ramos, Y.; Cruz, L. J.; Furic, R.; Côté, S.; Gravel, C.; Tulla-Puche, J.; Albericio, F. J Comb Chem 2006, 8, 213–220.
9. Cruz, L. J.; Cuevas, C.; Cañedo, L. M.; Giralt, E.; Albericio, F. J Org Chem 2006, 71, 3339–3344.
10. Benoiton N. L. Chemistry of Peptide Synthesis; CRC Press: Boca Raton, FL, 2006.
11. Albericio, F.; Chinchilla, R.; Dodsworth, D.J.; Nájera, C. Org Prep Proc Int 2001, 33, 203–303.
12. Carpino, L.; El-Faham, A.; Minor, C. A.; Albericio, F. Chem Comm 1994, 201–203.
13. Carpino, L. A.; El-Faham, A. J Am Chem Soc 1995, 117, 5401–5402.
14. Zhang, L.; Goldammer, C.; Henkel, B.; Zühl, F.; Panhaus, G.; Jungs, G.; Bayer, E. In Innovation and Perspectives in Solid Phase Synthesis, Epton, R., Ed.; Mayflower: Birmingham, 1994; pp 711–716.
15. Seebach, D.; Thaler, A.; Back, A. K. Helv Chim Acta 1989, 72, 857–867.
16. Toniolo, C.; Bonora, G. M.; Mutter, M. Makromol Chem 1981, 182, 2007–2014.
17. Hyde, C.; Johnson, T.; Owen, D.; Quibell, M.; Sheppard, R. C. Int J Pept Protein Res 1994, 43, 431–440.
18. Sasikumar, P. G.; Kumar, K. S.; Rajasekharan Pillai, V. N. J Pept Res 2003, 62, 1–10.
19. Alesso, S. M.; Yu, Z.; Pears, D.; Worthington, P. A.; Luke, R. W. A.; Bradley, M. Tetrahedron 2003, 59, 7163–7169.
20. Mutter, M.; Nefzi, A.; Sato, T.; Sun, X.; Wahl, T.; Wuhr, T. Pept Res 1995, 8, 145–153.
21. White, P.; Keyte, J. W.; Bailey, K.; Bloomberg, G. J Pept Sci 2004, 10, 18–26.
22. Abedini, A.; Raleigh, D. P. Org Lett 2005, 7(4), 693–696.
23. Renil, M.; Meldal, M. Tetrahedron Lett 1996, 37, 6185–6188.
24. Rademan, J.; Grötli, M.; Meldal, M.; Bock, K. J Am Chem Soc 1999, 121, 5459–5466.
25. Côté, S. PCT Int Appl 2005, WO 2005012277 A1 20050210 CAN 142: 198979 AN 2005: 120909.
26. Meldal, M. In: Methods in Enzymology, Solid-Phase Peptide Synthesis; Fields, G. B., Ed.; Academic Press: Orlando, FL, 1997; Vol 289; pp 83–104.
27. Lelièvre, D.; Turpin, O.; El Kazzouli, S; Delmas, A. Tetrahedron 2002, 58, 5525–5533.
28. Chung, C.; Cooke, R. M.; Proudfoot, A. E. I.; Wells, T. N. C. Biochemistry 1995, 34, 9307–9314.



10970282a, 2006, 6, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/bip.20564 by Universidad de la Rioja, Wiley Online Library on [08/02/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License